 |
|
|
| |
Effect of tesamorelin on risk of development or progression of diabetic retinopathy and glycemic control in HIV-infected subjects with diabetes and central adiposity
|
| |
| |
Dec 3 2020
Brown TT, Bedimo R, Goss OG, McGary CS and de Chantal M
•Enrollment was much slower than anticipated and the study was stopped prematurely as it became clear that the primary goal of the study would not be feasible.
•The population was middle aged, mostly male, mostly white, and had a mean BMI in the obese range.
•Very few had diabetic retinopathy at baseline
•The median A1c was in the low 7 range in both arms, with some variation
•Over the course of the study, IGF-1 increased by the expected magnitude in the tesamorelin arm, suggesting good adherence to the study drug
•It should be noted that the numbers of participants at each timepoint was lower at baseline, and there was incomplete data collection for IGF-1 at 18, 24, 30 months,
but even at 36 months the number of people remaining in the study was lower than at baseline.
|
| |
|
|
|
|
|
